MX2023012338A - Compuesto como antagonista del receptor de adenosina a2a y composicion farmaceutica que comprende al mismo. - Google Patents
Compuesto como antagonista del receptor de adenosina a2a y composicion farmaceutica que comprende al mismo.Info
- Publication number
- MX2023012338A MX2023012338A MX2023012338A MX2023012338A MX2023012338A MX 2023012338 A MX2023012338 A MX 2023012338A MX 2023012338 A MX2023012338 A MX 2023012338A MX 2023012338 A MX2023012338 A MX 2023012338A MX 2023012338 A MX2023012338 A MX 2023012338A
- Authority
- MX
- Mexico
- Prior art keywords
- same
- adenosine
- pharmaceutical composition
- receptor antagonist
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 title 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210053352 | 2021-04-23 | ||
| PCT/IB2022/053721 WO2022224180A1 (en) | 2021-04-23 | 2022-04-21 | Compound as adenosine a2a receptor antagonist and pharmaceutical composition comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012338A true MX2023012338A (es) | 2023-10-30 |
Family
ID=83722733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012338A MX2023012338A (es) | 2021-04-23 | 2022-04-21 | Compuesto como antagonista del receptor de adenosina a2a y composicion farmaceutica que comprende al mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240217978A1 (https=) |
| EP (1) | EP4326724A4 (https=) |
| JP (1) | JP7646873B2 (https=) |
| KR (1) | KR102863028B1 (https=) |
| CN (1) | CN117120443A (https=) |
| AU (1) | AU2022262777C1 (https=) |
| BR (1) | BR112023021918A2 (https=) |
| CA (1) | CA3207935A1 (https=) |
| MX (1) | MX2023012338A (https=) |
| TW (1) | TWI838736B (https=) |
| WO (1) | WO2022224180A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023296161A1 (en) * | 2022-06-13 | 2025-01-02 | Alivexis, Inc. | Azacycloalkyl carbonyl cyclic amine compound |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0459702A1 (en) * | 1990-05-29 | 1991-12-04 | Zeneca Limited | Azole Derivatives |
| US5356894A (en) | 1990-05-29 | 1994-10-18 | Rodney Peter W | Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist |
| CA2148502A1 (en) * | 1993-09-06 | 1995-03-16 | Fumio Suzuki | Antidepressants |
| US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US6664252B2 (en) * | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| CA2459304A1 (en) * | 2001-09-13 | 2003-03-20 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| IL161573A0 (en) * | 2001-11-30 | 2004-09-27 | Schering Corp | [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS |
| JPWO2003068776A1 (ja) * | 2002-02-15 | 2005-06-02 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| WO2004092173A2 (en) | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
| EP3810610A1 (en) * | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| JP7197206B2 (ja) * | 2018-06-26 | 2022-12-27 | チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド | Ａ２ａ受容体拮抗薬として用いられるトリアゾロトリアジン誘導体 |
| AU2019383948A1 (en) * | 2018-11-20 | 2021-05-20 | Merck Sharp & Dohme Llc | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| CN112028891B (zh) * | 2019-07-30 | 2022-07-05 | 厦门宝太生物科技股份有限公司 | 腺苷受体拮抗剂 |
-
2022
- 2022-04-21 MX MX2023012338A patent/MX2023012338A/es unknown
- 2022-04-21 AU AU2022262777A patent/AU2022262777C1/en active Active
- 2022-04-21 TW TW111115277A patent/TWI838736B/zh active
- 2022-04-21 EP EP22791230.0A patent/EP4326724A4/en active Pending
- 2022-04-21 KR KR1020220049770A patent/KR102863028B1/ko active Active
- 2022-04-21 BR BR112023021918A patent/BR112023021918A2/pt unknown
- 2022-04-21 CA CA3207935A patent/CA3207935A1/en active Pending
- 2022-04-21 US US18/287,743 patent/US20240217978A1/en active Pending
- 2022-04-21 WO PCT/IB2022/053721 patent/WO2022224180A1/en not_active Ceased
- 2022-04-21 CN CN202280022844.9A patent/CN117120443A/zh active Pending
- 2022-04-21 JP JP2023565293A patent/JP7646873B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024515739A (ja) | 2024-04-10 |
| JP7646873B2 (ja) | 2025-03-17 |
| KR102863028B1 (ko) | 2025-09-22 |
| AU2022262777C1 (en) | 2025-02-13 |
| WO2022224180A1 (en) | 2022-10-27 |
| TW202302593A (zh) | 2023-01-16 |
| BR112023021918A2 (pt) | 2023-12-19 |
| AU2022262777A1 (en) | 2023-09-21 |
| US20240217978A1 (en) | 2024-07-04 |
| CN117120443A (zh) | 2023-11-24 |
| TWI838736B (zh) | 2024-04-11 |
| AU2022262777B2 (en) | 2024-11-07 |
| EP4326724A4 (en) | 2025-03-26 |
| CA3207935A1 (en) | 2022-10-27 |
| EP4326724A1 (en) | 2024-02-28 |
| KR20220146348A (ko) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551454A1 (en) | Pyrazolyl derivatives useful as anti-cancer agents | |
| MX2021003739A (es) | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. | |
| MX2020000268A (es) | Agonista de fxr. | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
| MX2024014628A (es) | Compuesto para inhibir o degradar bcl6 y uso de este en farmacia | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| NO20073357L (no) | 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien | |
| MX2017012393A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| MA32812B1 (fr) | Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale | |
| MX2010007375A (es) | Nuevos derivados de lupano. | |
| TW200714583A (en) | Substituted gamma lactams as therapeutic agents | |
| MY209754A (en) | Amide derivative and preparation method therefore and use thereof in medicine | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| MX2022006519A (es) | Medicamento conjugado con polietilenglicol, metodo de preparacion del mismo y uso del mismo. | |
| MX2023012971A (es) | Agonistas del receptor de orexina y sus usos. | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| MX2023004033A (es) | Espiro derivados de alfa-d-galactopiranosidos. | |
| CA3155875A1 (en) | BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE | |
| MX2024000999A (es) | Antagonista de molécula pequeña de lpa1. | |
| PH12022553516A1 (en) | Novel pyrazole derivatives | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| MX2023012338A (es) | Compuesto como antagonista del receptor de adenosina a2a y composicion farmaceutica que comprende al mismo. | |
| MX2022006104A (es) | Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma. |